Biological E Ltd’s Corbevax has got Emergency Use Authorisation (EUA) for adolescents between 12 and 18 years in India.
The vaccine-maker announced the news in a statement today. Also, this is the second COVID-19 vaccine for children and teens that has got emergency use authorization in India.
Till now India had been administering Bharat Biotech’s Covaxin to teenagers between 15 and 18 years old since January 3.
The EUA for Corbevax’s restricted use among adults was cleared by the DCGI in December 2019.
The testing capacity is seeing a rapid progress across the country. Furthermore, the weekly positivity rate in India currently stands at 2.12 per cent.
“BE received the approval for restricted use in an emergency situation in adolescents aged 12 to 18 years based on interim results (of the ongoing phase II/III clinical study),” Biological E said in the statement Monday.
India’s cumulative COVID-19 vaccination coverage crossed 175.46 crores with the administration of over 7 lakh doses in the past 24 hours, the Union Health Ministry informed Monday.
Moreover, Corbevax comes as India’s first homegrown “receptor-binding domain protein sub-unit COVID-19 vaccine“.
In September 2021, Biological E also got permission to conduct phase II and III clinical trials on Corbevax in children and adolescents aged 5 to 18 years.
Corbevax is given through intramuscular route with two doses scheduled 28 days apart; it is stored at 2 to 8 degree Celsius. The vaccine comes in 0.5 ml (single dose), 5 ml (10 doses) and 10 ml (20 doses) vial packs.
YOU MAY ALSO WATCH:
ALSO READ | Covid-19 Entering Endemic Stage In India? Experts Speak
